Biggest News Aggregation in the World
📰 Mid Caps News

Page 32 - Mid Caps News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Mid Caps. Real-time updates on events, politics, business and more.

Nicox: Half-year liquidity contract statement with Kepler

-        Number of executions on sell side on semester: 609 -        Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01 -        Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94 •        the following resources appeared on the liquidity account when the activity started: -        0 shares -        € 500,000.00 The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, ...
New York United States Provence Alpes Côd Azur France General United Kingdom City Of

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux July 6, 2021 - release at 7:30 am CET Sophia Antipolis, France Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021: - 218,919 shares - Number of executions on sell side on semester: 1,298 - Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01 - Traded volume on sell side on sem...
New York United States Provence Alpes Côd Azur France General United Kingdom Gavin Spencer

Nicox to Receive $2 Million from Ocumension Therapeutics as

® Agreement Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE ® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full adva...
New York United States Provence Alpes Côd Azur France General United Kingdom South Korea

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial July 2nd, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period. Top-line results are expected to be announced in September 2021. " ...
New York United States Provence Alpes Côd Azur France General United Kingdom Gavin Spencer

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science